Skip to main content

Research Repository

Advanced Search

CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer (2021)
Journal Article
Uzor, S., Oltean, S., Ladomery, M., Alqasem, A., Perks, C., Wilson, I. D., …Iida, K. (2021). CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer. Scientific Reports, 11(1), https://doi.org/10.1038/s41598-021-86908-6

Dysregulation of alternative splicing is a feature of cancer, both in aetiology and progression. It occurs because of mutations in splice sites or sites that regulate splicing, or because of the altered expression and activity of splice factors and o... Read More about CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer.